These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16135901)

  • 1. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.
    Manosuthi W; Sungkanuparph S; Thakkinstian A; Vibhagool A; Kiertiburanakul S; Rattanasiri S; Prasithsirikul W; Sankote J; Mahanontharit A; Ruxrungtham K
    AIDS; 2005 Sep; 19(14):1481-6. PubMed ID: 16135901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
    Friedland G; Khoo S; Jack C; Lalloo U
    J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
    Patel A; Patel K; Patel J; Shah N; Patel B; Rani S
    J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1166-9. PubMed ID: 15319677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin.
    Mariana N; Purwantyastuti ; Instiaty ; Rusli A
    Acta Med Indones; 2016 Jan; 48(1):10-6. PubMed ID: 27241539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
    Manosuthi W; Kiertiburanakul S; Sungkanuparph S; Ruxrungtham K; Vibhagool A; Rattanasiri S; Thakkinstian A
    AIDS; 2006 Jan; 20(1):131-2. PubMed ID: 16327334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
    J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz plasma concentrations and efficiency.
    López-Cortés LF; de Alarcón A; Viciana P
    AIDS; 2001 Jun; 15(9):1192-4. PubMed ID: 11416729
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
    Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous determination of rifampicin and efavirenz in plasma.
    Boffito M; Tija J; Reynolds HE; Hoggard PG; Bonora S; Di Perri G; Back DJ
    Ther Drug Monit; 2002 Oct; 24(5):670-4. PubMed ID: 12352941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
    Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
    PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
    Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
    Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
    JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
    BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
    Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
    Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y; Nuttall JJ; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2009 Apr; 50(5):439-43. PubMed ID: 19223781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Mankatitham W; Lueangniyomkul A; Thongyen S; Eampokarap B; Uttayamakul S; Suwanvattana P; Kaewsaard S; Ruxrungtham K;
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4545-8. PubMed ID: 19667281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.
    Brennan-Benson P; Lyus R; Harrison T; Pakianathan M; Macallan D
    AIDS; 2005 Sep; 19(14):1541-3. PubMed ID: 16135909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
    Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
    Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.